Multiple Sclerosis Market in US 2025-2029

Description

List of Tables

The multiple sclerosis market in us is forecasted to grow by USD 4.99 bn during 2024-2029, accelerating at a CAGR of 6.2% during the forecast period. The report on the multiple sclerosis market in us provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by strong pipeline of vendors, rising prevalence of multiple sclerosis, and disease-modifying therapies.

Technavio's multiple sclerosis market in us is segmented as below:

Market Scope
Base Year	2025
End Year	2029
Series Year	2025-2029
Growth Momentum	Accelerate
YOY 2025	5.8%
CAGR	6.2%
Incremental Value	$4.99 bn

By Route Of Administration

Parenteral
Oral

By Type

Biologics
Small molecules

By Geographical Landscape

North America

This study identifies the rising strategic alliances and partnerships among vendors as one of the prime reasons driving the multiple sclerosis market in us growth during the next few years. Also, rising product approval and stem cell treatment for multiple sclerosis will lead to sizable demand in the market.

The report on the multiple sclerosis market in us covers the following areas:

Multiple Sclerosis Market in US sizing
Multiple Sclerosis Market in US forecast
Multiple Sclerosis Market in US industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading multiple sclerosis market in us vendors that include AB Science SA, Astellas Pharma Inc., Bayer AG, Biogen Inc., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., GeNeuro SA, Glenmark Pharmaceuticals Ltd., Inno BioScience LLC, Johnson and Johnson Inc., Mapi Pharma Ltd., MediciNova Inc., Merck KGaA, Novartis AG, Opexa Therapeutics Inc., Pfizer Inc., Sanofi SA, Sobel Network Shipping Co. Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc.. Also, the multiple sclerosis market in us analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR72567

1 Executive Summary

1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Country Market Characteristics
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
- Overview on criticality of inputs and factors of differentiation
2.3 Factors of disruption
- Overview on factors of disruption
2.4 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029

3 Market Landscape

3.1 Market ecosystem
- Parent Market
- Data Table on - Parent Market
3.2 Market characteristics
- Market characteristics analysis
3.3 Value chain analysis
- Value chain analysis

4 Market Sizing

4.1 Market definition
- Offerings of companies included in the market definition
4.2 Market segment analysis
- Market segments
4.3 Market size 2024
4.4 Market outlook: Forecast for 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ billion)
- Data Table on US - Market size and forecast 2024-2029 ($ billion)
- Chart on US: Year-over-year growth 2024-2029 (%)
- Data Table on US: Year-over-year growth 2024-2029 (%)

5 Historic Market Size

5.1 Multiple Sclerosis Market in US 2019 - 2023
- Historic Market Size - Data Table on Multiple Sclerosis Market in US 2019 - 2023 ($ billion)
5.2 Route of Administration segment analysis 2019 - 2023
- Historic Market Size - Route of Administration Segment 2019 - 2023 ($ billion)
5.3 Type segment analysis 2019 - 2023
- Historic Market Size - Type Segment 2019 - 2023 ($ billion)

6 Qualitative Analysis

6.1 Impact of AI on Multiple Sclerosis Market in US

7 Five Forces Analysis

7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
7.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029

8 Market Segmentation by Route of Administration

8.1 Market segments
- Chart on Route of Administration - Market share 2024-2029 (%)
- Data Table on Route of Administration - Market share 2024-2029 (%)
8.2 Comparison by Route of Administration
- Chart on Comparison by Route of Administration
- Data Table on Comparison by Route of Administration
8.3 Parenteral - Market size and forecast 2024-2029
- Chart on Parenteral - Market size and forecast 2024-2029 ($ billion)
- Data Table on Parenteral - Market size and forecast 2024-2029 ($ billion)
- Chart on Parenteral - Year-over-year growth 2024-2029 (%)
- Data Table on Parenteral - Year-over-year growth 2024-2029 (%)
8.4 Oral - Market size and forecast 2024-2029
- Chart on Oral - Market size and forecast 2024-2029 ($ billion)
- Data Table on Oral - Market size and forecast 2024-2029 ($ billion)
- Chart on Oral - Year-over-year growth 2024-2029 (%)
- Data Table on Oral - Year-over-year growth 2024-2029 (%)
8.5 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ billion)
- Data Table on Market opportunity by Route of Administration ($ billion)

9 Market Segmentation by Type

9.1 Market segments
- Chart on Type - Market share 2024-2029 (%)
- Data Table on Type - Market share 2024-2029 (%)
9.2 Comparison by Type
- Chart on Comparison by Type
- Data Table on Comparison by Type
9.3 Biologics - Market size and forecast 2024-2029
- Chart on Biologics - Market size and forecast 2024-2029 ($ billion)
- Data Table on Biologics - Market size and forecast 2024-2029 ($ billion)
- Chart on Biologics - Year-over-year growth 2024-2029 (%)
- Data Table on Biologics - Year-over-year growth 2024-2029 (%)
9.4 Small molecules - Market size and forecast 2024-2029
- Chart on Small molecules - Market size and forecast 2024-2029 ($ billion)
- Data Table on Small molecules - Market size and forecast 2024-2029 ($ billion)
- Chart on Small molecules - Year-over-year growth 2024-2029 (%)
- Data Table on Small molecules - Year-over-year growth 2024-2029 (%)
9.5 Market opportunity by Type
- Market opportunity by Type ($ billion)
- Data Table on Market opportunity by Type ($ billion)

10 Customer Landscape

10.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

11 Drivers, Challenges, and Opportunity/Restraints

11.1 Market drivers
11.2 Market challenges
11.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
11.4 Market opportunities/restraints

12 Competitive Landscape

12.1 Overview
12.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
12.3 Landscape disruption
- Overview on factors of disruption
12.4 Industry risks
- Impact of key risks on business

13 Competitive Analysis

13.1 Companies profiled
- Companies covered
13.2 Company ranking index
- Company ranking index
13.3 Market positioning of companies
- Matrix on companies position and classification
13.4 Bayer AG
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key news
- Bayer AG - Key offerings
- Bayer AG - Segment focus
- SWOT
13.5 Biogen Inc.
- Biogen Inc. - Overview
- Biogen Inc. - Product / Service
- Biogen Inc. - Key news
- Biogen Inc. - Key offerings
- SWOT
13.6 Bristol Myers Squibb Co.
- Bristol Myers Squibb Co. - Overview
- Bristol Myers Squibb Co. - Product / Service
- Bristol Myers Squibb Co. - Key news
- Bristol Myers Squibb Co. - Key offerings
- SWOT
13.7 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
13.8 Johnson and Johnson Inc.
- Johnson and Johnson Inc. - Overview
- Johnson and Johnson Inc. - Business segments
- Johnson and Johnson Inc. - Key news
- Johnson and Johnson Inc. - Key offerings
- Johnson and Johnson Inc. - Segment focus
- SWOT
13.9 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
13.10 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Product / Service
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- SWOT
13.11 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
13.12 Teva Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd. - Overview
- Teva Pharmaceutical Industries Ltd. - Business segments
- Teva Pharmaceutical Industries Ltd. - Key news
- Teva Pharmaceutical Industries Ltd. - Key offerings
- Teva Pharmaceutical Industries Ltd. - Segment focus
- SWOT
13.13 Viatris Inc.
- Viatris Inc. - Overview
- Viatris Inc. - Business segments
- Viatris Inc. - Key news
- Viatris Inc. - Key offerings
- Viatris Inc. - Segment focus
- SWOT

14 Appendix

14.1 Scope of the report
14.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
14.3 Currency conversion rates for US$
- Currency conversion rates for US$
14.4 Research methodology
- Research methodology
14.5 Data procurement
- Information sources
14.6 Data validation
- Data validation
14.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
14.8 Data synthesis
- Data synthesis
14.9 360 degree market analysis
- 360 degree market analysis
14.10 List of abbreviations
- List of abbreviations